相似文献
1
Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.
Drug Discov Today. 2010 Aug;15(15-16):622-9. doi: 10.1016/j.drudis.2010.06.011. Epub 2010 Jun 25.
2
Rho kinase (ROCK) inhibitors.
J Cardiovasc Pharmacol. 2007 Jul;50(1):17-24. doi: 10.1097/FJC.0b013e318070d1bd.
3
Does it matter whether or not a lipid-lowering agent inhibits Rho kinase?
Curr Atheroscler Rep. 2007 Nov;9(5):384-8. doi: 10.1007/s11883-007-0049-9.
4
2015 ATVB Plenary Lecture: translational research on rho-kinase in cardiovascular medicine.
Arterioscler Thromb Vasc Biol. 2015 Aug;35(8):1756-69. doi: 10.1161/ATVBAHA.115.305353. Epub 2015 Jun 11.
5
Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges.
Expert Opin Ther Targets. 2005 Aug;9(4):715-36. doi: 10.1517/14728222.9.4.715.
6
Vascular rho kinases and their potential therapeutic applications.
Curr Opin Drug Discov Devel. 2007 Sep;10(5):590-6.
7
Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease.
Trends Pharmacol Sci. 2011 Mar;32(3):167-73. doi: 10.1016/j.tips.2010.12.006. Epub 2011 Jan 16.
8
Rho kinase inhibitors as potential therapeutic agents for cardiovascular diseases.
Curr Opin Investig Drugs. 2003 Sep;4(9):1065-75.
9
Rho kinase as a therapeutic target in cardiovascular disease.
Future Cardiol. 2011 Sep;7(5):657-71. doi: 10.2217/fca.11.51.
10
Rho kinase inhibitors: potential treatments for diabetes and diabetic complications.
Curr Pharm Des. 2012;18(20):2964-73. doi: 10.2174/138161212800672688.
引用本文的文献
1
Involvement of RhoA/ROCK Signaling Pathway in Methamphetamine-Induced Blood-Brain Barrier Disruption.
Biomolecules. 2025 Feb 27;15(3):340. doi: 10.3390/biom15030340.
2
Molecular Mechanisms of Alzheimer's Disease Induced by Amyloid-β and Tau Phosphorylation Along with RhoA Activity: Perspective of RhoA/Rho-Associated Protein Kinase Inhibitors for Neuronal Therapy.
Cells. 2025 Jan 10;14(2):89. doi: 10.3390/cells14020089.
3
Role of Rho-associated kinases and their inhibitor fasudil in neurodegenerative diseases.
Front Neurosci. 2024 Nov 19;18:1481983. doi: 10.3389/fnins.2024.1481983. eCollection 2024.
4
Ocular effects of Rho kinase (ROCK) inhibition: a systematic review.
Eye (Lond). 2024 Dec;38(18):3418-3428. doi: 10.1038/s41433-024-03342-4. Epub 2024 Sep 16.
5
RhoA/rho kinase pathway activation in age-associated endothelial cell dysfunction and thrombosis.
J Cell Mol Med. 2024 Apr;28(8):e18153. doi: 10.1111/jcmm.18153.
6
Multiscale imaging of corneal endothelium damage and Rho-kinase inhibitor application in mouse models of acute ocular hypertension.
Biomed Opt Express. 2024 Jan 25;15(2):1102-1114. doi: 10.1364/BOE.510432. eCollection 2024 Feb 1.
7
Acceptorless cross-dehydrogenative coupling for C(sp)-H heteroarylation mediated by a heterogeneous GaN/ketone photocatalyst/photosensitizer system.
Commun Chem. 2023 Sep 1;6(1):181. doi: 10.1038/s42004-023-00947-w.
8
Automated analysis of vessel morphometry in retinal images from a Danish high street optician setting.
PLoS One. 2023 Aug 24;18(8):e0290278. doi: 10.1371/journal.pone.0290278. eCollection 2023.
9
Pharmaceutical Therapies for Necroptosis in Myocardial Ischemia-Reperfusion Injury.
J Cardiovasc Dev Dis. 2023 Jul 17;10(7):303. doi: 10.3390/jcdd10070303.
10
CCL2 promotes proliferation, migration and angiogenesis through the MAPK/ERK1/2/MMP9, PI3K/AKT, Wnt/β‑catenin signaling pathways in HUVECs.
Exp Ther Med. 2022 Dec 27;25(2):77. doi: 10.3892/etm.2022.11776. eCollection 2023 Feb.
本文引用的文献
1
Role of rho-kinase in the regulation of vascular tone in hypertensive renal transplant recipients.
Atherosclerosis. 2009 Dec;207(2):567-72. doi: 10.1016/j.atherosclerosis.2009.05.025. Epub 2009 May 27.
2
Current status of rho-associated kinases (ROCKs) in coronary atherosclerosis and vasospasm.
Cardiovasc Hematol Agents Med Chem. 2009 Oct;7(4):322-30. doi: 10.2174/187152509789541891.
3
Involvement of Rho-kinase in tumor necrosis factor-alpha-induced interleukin-6 release from C6 glioma cells.
Neurochem Int. 2009 Nov;55(6):438-45. doi: 10.1016/j.neuint.2009.04.016. Epub 2009 May 7.
4
PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma.
Hum Pathol. 2009 Oct;40(10):1434-40. doi: 10.1016/j.humpath.2009.02.008. Epub 2009 May 7.
5
The effect of the H-1152P, a potent Rho-associated coiled coil-formed protein kinase inhibitor, in rabbit normal and ocular hypertensive eyes.
Curr Eye Res. 2009 Apr;34(4):282-6. doi: 10.1080/02713680902783763.
6
RhoA and Rho kinase activation in human pulmonary hypertension: role of 5-HT signaling.
Am J Respir Crit Care Med. 2009 Jun 15;179(12):1151-8. doi: 10.1164/rccm.200805-691OC. Epub 2009 Mar 19.
7
Statins inhibit Rho kinase activity in patients with atherosclerosis.
Atherosclerosis. 2009 Aug;205(2):517-21. doi: 10.1016/j.atherosclerosis.2008.12.023. Epub 2008 Dec 24.
8
Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation.
Circulation. 2009 Jan 6;119(1):131-8. doi: 10.1161/CIRCULATIONAHA.108.813311. Epub 2008 Dec 15.
9
A major haplotype block at the rho-associated kinase 2 locus is associated with a lower risk of hypertension in a recessive manner: the HYPGENE study.
Hypertens Res. 2008 Aug;31(8):1651-7. doi: 10.1291/hypres.31.1651.
10
Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin.
Blood Coagul Fibrinolysis. 2008 Oct;19(7):709-18. doi: 10.1097/MBC.0b013e32830b2891.
Zotero 插件